Letters
OBSERVATIONS ON THE MECHANISM OF OMALIZUMAB AS A STEROID-SPARING AGENT IN AUTOIMMUNE OR CHRONIC IDIOPATHIC URTICARIA AND ANGIOEDEMA

https://doi.org/10.1016/S1081-1206(10)60069-5Get rights and content

REFERENCES (16)

There are more references available in the full text version of this article.

Cited by (26)

  • Differential Diagnosis of Chronic Urticaria and Angioedema Based on Molecular Biology, Pharmacology, and Proteomics

    2017, Immunology and Allergy Clinics of North America
    Citation Excerpt :

    The acquired form of angioedema associated with deficiency of C1 inhibitor proteins is usually associated with either malignant (type 1) or autoimmune disease (type 2) also recently characterized both by molecular mechanisms and response to therapy.13 Autoreactive antibodies are also present in many cases of chronic urticaria as are associations with other autoimmune syndromes such as autoimmune thyroid disease, although the mechanism underlying these associations is debated.14–17 Improved methods of immune assays such as peptide arrays and proteomics can provide detailed molecular information about the targets of autoreactive antibodies in some forms of chronic urticaria, as will be discussed in more detail elsewhere in this review.

  • Biologics in Chronic Urticaria

    2017, Immunology and Allergy Clinics of North America
    Citation Excerpt :

    The European guidelines are slightly different, with the addition of omalizumab as the third step after the failure of nonsedating antihistamine at standard and high doses.44 Beyond CU, omalizumab has been used in urticarial vasculitis30 and a variety of physical forms of urticaria. These include cholinergic urticaria,29,45 cold-induced urticaria,26,46,47 delayed pressure urticaria,46,48,49 heat urticaria,46,50,51 aquagenic urticaria,52 dermatographism,46 and solar urticaria.31,46,53

  • Treatment of Chronic Urticaria

    2014, Immunology and Allergy Clinics of North America
  • Diagnosis and treatment of urticaria and angioedema: A worldwide perspective

    2012, World Allergy Organization Journal
    Citation Excerpt :

    Mycophenolate mofetil seems to be a useful treatment option for patients with CU who do not respond to antihistamines and/or corticosteroids with experience limited to observational studies [157, 158]. Recently, a growing number of studies evaluating the effectiveness of omalizumab (humanized monoclonal anti-IgE antibodies) in different subsets of antihistamine unresponsive CU/angioedema patients have been reported [36, 39, 159–166]. Although the current experience with omalizumab in the treatment of CU is encouraging, rare cases of omalizumab failure have been reported [167].

  • Autoimmune disease: A role for new anti-viral therapies?

    2011, Autoimmunity Reviews
    Citation Excerpt :

    Chronic idiopathic urticaria (CIU, also termed chronic spontaneous urticaria or chronic autoimmune urticaria) is in many cases an autoimmune syndrome [1,2]. In some cases CIU is associated with autoimmune thyroid diseases [3,4], and in many cases CIU is associated with autoantibodies binding to and activating the IgE receptor, suggesting that autoantibodies may be part of the pathogenic mechanism of the disease, although other inflammatory mechanisms may also play a role [5]. Skin biopsies in CIU show an infiltrate of lymphocytes and other inflammatory cells and cytokines in contrast to allergic, post viral or physical urticaria, also consistent with an autoimmune pathogenesis.

View all citing articles on Scopus

Disclosures: Author has nothing to disclose.

View full text